A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis.

Trial Profile

A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Romosozumab (Primary) ; Alendronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ARCH
  • Sponsors Amgen
  • Most Recent Events

    • 11 Sep 2017 Results published in the New England Journal of Medicine
    • 11 Sep 2017 According to an Amgen media release, results from this trial were presented at the Annual Meeting of the American Society for Bone Mineral Research (ASBMR) 2017.
    • 11 Sep 2017 According to an Amgen media release, results from this trial were published in the New England Journal of Medicine (NEJM).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top